Rock Springs Capital Management LP Grows Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Rock Springs Capital Management LP raised its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 8.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 351,828 shares of the company’s stock after purchasing an additional 27,813 shares during the period. Rock Springs Capital Management LP owned 0.24% of Centessa Pharmaceuticals worth $13,975,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Eagle Health Investments LP grew its stake in shares of Centessa Pharmaceuticals by 107.8% during the 1st quarter. Eagle Health Investments LP now owns 214,291 shares of the company’s stock valued at $8,512,000 after buying an additional 111,191 shares during the period. Torno Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth $794,000. Maverick Capital Ltd. raised its position in shares of Centessa Pharmaceuticals by 12.8% in the 1st quarter. Maverick Capital Ltd. now owns 1,854,488 shares of the company’s stock worth $73,660,000 after buying an additional 210,764 shares during the period. Rangeley Capital LLC purchased a new position in shares of Centessa Pharmaceuticals in the 1st quarter worth $357,000. Finally, Weiss Asset Management LP acquired a new position in Centessa Pharmaceuticals in the first quarter valued at $20,273,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $40.50 on Tuesday. The firm’s fifty day simple moving average is $40.16 and its 200 day simple moving average is $33.89. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $12.74 and a twelve month high of $40.56. The firm has a market capitalization of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, equities research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of research reports. Truist Financial downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a research report on Monday, April 13th. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Lifesci Capital cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Wells Fargo & Company cut Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $35.00 to $42.00 in a report on Monday, April 20th. Finally, Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.